Valuation: SUSMED,Inc.

Market Cap 14.58B 92.63M 81.28M 76.77M 69.96M 131M 8.88B 132M 919M 356M 4.54B 348M 340M P/E 2024
-28.1x
P/E 2025 -34.4x
Enterprise Value 10.18B 64.68M 56.76M 53.61M 48.85M 91.45M 6.2B 92.1M 641M 248M 3.17B 243M 238M EV / Sales 2024
15.2x
EV / Sales 2025 12.7x
Free-Float
46.74%
Yield 2024 *
-
Yield 2025 -
1 day+1.15%
1 week+1.39%
Current month-3.30%
1 month-22.85%
3 months-45.12%
6 months-55.97%
Current year-47.99%
1 week 428
Extreme 428
444
1 month 392
Extreme 392
506
Current year 392
Extreme 392
1,231
1 year 392
Extreme 392
1,231
3 years 375
Extreme 375
1,658
5 years 375
Extreme 375
2,500
10 years 375
Extreme 375
2,500
Manager TitleAgeSince
President 45 2016-01-31
Chief Administrative Officer 49 2021-04-30
Chief Tech/Sci/R&D Officer 43 2019-08-31
Director TitleAgeSince
Director/Board Member 45 2015-07-30
Director/Board Member 43 2019-08-31
Director/Board Member 49 2021-04-30
Change 5-day change 1-year change 3-year change Capi.($)
+1.15%+1.39%-49.19%-71.98% 46.9M
-0.68%-1.76%-19.87%+53.95% 212B
+0.58%+1.06%+51.60%+124.35% 118B
-0.73%-2.86%-24.27%-44.44% 108B
-0.24%-1.09%-29.60%-41.80% 78.59B
+0.08%+1.12%-26.99%-8.87% 58.2B
+0.88%+1.23%+10.63%+118.97% 44.4B
-1.41%-4.87%-32.64%-32.15% 42.26B
+0.48%+0.06%+1.52%+194.24% 40.58B
-5.54%+7.03%+114.05%+143.41% 34.12B
Average -0.54%+0.13%-0.48%+43.57% 73.68B
Weighted average by Cap. -0.49%-0.66%-2.15%+46.54%

Financials

2024 2025
Net sales 342M 2.17M 1.91M 1.8M 1.64M 3.07M 208M 3.09M 21.55M 8.35M 106M 8.16M 7.98M 462M 2.94M 2.58M 2.43M 2.22M 4.15M 281M 4.18M 29.12M 11.28M 144M 11.02M 10.78M
Net income -357M -2.27M -1.99M -1.88M -1.71M -3.21M -217M -3.23M -22.5M -8.71M -111M -8.52M -8.33M -298M -1.89M -1.66M -1.57M -1.43M -2.68M -181M -2.7M -18.78M -7.27M -92.72M -7.11M -6.96M
Net Debt -4.85B -30.79M -27.02M -25.52M -23.26M -43.54M -2.95B -43.85M -305M -118M -1.51B -116M -113M -4.4B -27.95M -24.52M -23.16M -21.11M -39.51M -2.68B -39.79M -277M -107M -1.37B -105M -103M
Logo SUSMED,Inc.
Susmed Inc is a Japan-based company mainly engaged in the digital therapeutics (DTx) development business. The Company operates through two business segments. The DTx Product segment is engaged in the development of application software products for treating diseases such as insomnia, breast cancer, chronic kidney diseases and others. The DTx Platform segment is engaged in the provision of general-purpose clinical trial systems and machine learning automatic analysis systems, as well as the provision of DTx development support services using systems.
Employees
-
Date Price Change Volume
26-09-25 JP¥439.00 +1.15% 113,100
26-09-24 JP¥434.00 +0.23% 195,900
26-09-18 JP¥433.00 +2.61% 180,000
26-09-17 JP¥422.00 +1.69% 692,500

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4263 Stock